Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series.

Q1 Medicine CNS Oncology Pub Date : 2019-06-01 Epub Date: 2019-07-11 DOI:10.2217/cns-2019-0007

Liang Yen Liu, Matthew S Ji, Nhung T Nguyen, Frances E Chow, Donna M Molaie, Sean T Pianka, Richard M Green, Linda M Liau, Benjamin M Ellingson, Phioanh L Nghiemphu, Timothy F Cloughesy, Albert Lai

{"title":"Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series.","authors":"Liang Yen Liu, Matthew S Ji, Nhung T Nguyen, Frances E Chow, Donna M Molaie, Sean T Pianka, Richard M Green, Linda M Liau, Benjamin M Ellingson, Phioanh L Nghiemphu, Timothy F Cloughesy, Albert Lai","doi":"10.2217/cns-2019-0007","DOIUrl":null,"url":null,"abstract":"Aim: Long-term survivors (LTS) after glioma recurrence while on bevacizumab (Bev) therapy are rarely reported in the current literature. The purpose of this case series is to confirm the existence of and describe a large cohort of recurrent glioma LTS treated with Bev (Bev-LTS). Patients & methods: We identified Bev-LTS as patients with post-Bev initiation survival times of ≥3 years among 1397 Bev treated recurrent glioma patients. Results: Among 962 grade-IV, 221 grade III, and 214 grade II Bev-treated glioma patients, we identified 28 (2.9%), 14 (6.3%) and 8 (3.7%) Bev-LTS patients, respectively. 45 Bev-LTS patients recurred on Bev, with 36 of those patients continuing therapy. Conclusion: Our study shows that a small portion of grade-IV, -III, and -II glioma patients can have long-term survival on Bev therapy even after Bev recurrence.","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":"8 2","pages":"CNS35"},"PeriodicalIF":0.0000,"publicationDate":"2019-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/cns-2019-0007","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/cns-2019-0007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/7/11 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 5

Abstract

Aim: Long-term survivors (LTS) after glioma recurrence while on bevacizumab (Bev) therapy are rarely reported in the current literature. The purpose of this case series is to confirm the existence of and describe a large cohort of recurrent glioma LTS treated with Bev (Bev-LTS). Patients & methods: We identified Bev-LTS as patients with post-Bev initiation survival times of ≥3 years among 1397 Bev treated recurrent glioma patients. Results: Among 962 grade-IV, 221 grade III, and 214 grade II Bev-treated glioma patients, we identified 28 (2.9%), 14 (6.3%) and 8 (3.7%) Bev-LTS patients, respectively. 45 Bev-LTS patients recurred on Bev, with 36 of those patients continuing therapy. Conclusion: Our study shows that a small portion of grade-IV, -III, and -II glioma patients can have long-term survival on Bev therapy even after Bev recurrence.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

贝伐单抗治疗复发性胶质瘤后的长期生存模式:一个病例系列。

目的:目前文献中很少报道胶质瘤复发后接受贝伐单抗治疗的长期幸存者(LTS)。本病例系列的目的是确认和描述一个用Bev治疗的复发性神经胶质瘤LTS (Bev-LTS)的大队列的存在。患者和方法:我们在1397例接受Bev治疗的复发性胶质瘤患者中，将Bev- lts确定为Bev起始生存期≥3年的患者。结果:在962例iv级、221例III级和214例II级bev治疗的胶质瘤患者中，我们分别确定了28例(2.9%)、14例(6.3%)和8例(3.7%)Bev-LTS患者。45例Bev- lts患者在Bev复发，其中36例患者继续治疗。结论:我们的研究表明，小部分iv级、-III级和-II级胶质瘤患者即使在Bev复发后也能通过Bev治疗获得长期生存。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊